Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

Completed · Phase 1

Conditions studied: Thrombosis

In brief

To estimate the pharmacokinetics of apixaban when administered as three different modified release formulation tablets relative to that when apixaban is administered as an immediate release tablet

Key facts

Study ID

NCT00914641

Run by

Pfizer

People needed

16

Starts

2009-06-01

Expected to finish

2009-08-01

Last updated by the study team

2009-08-25

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male or female patients
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2

You may not qualify if…

• Any condition possibly affecting drug absorption
• History or evidence of abnormal bleeding or clotting disorder

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.